- Australia
- Austria
- Belgium
- Brazil
- Chile
- China
- Colombia
- France
- Germany
- India
- Italy
- Japan
- Korea
- Mexico
- Netherlands
- Switzerland
- South Africa
- Spain
- Taiwan
- United Kingdom
- USA
Contact
- Français
GBT€26.70

Our Group
Products & Solutions
- MRI
  - Home of MRI Innovations
  - Injectors, Accessories & Consumables
  - Service & Support
    - OptiProtect™ 3S
  - Digital Solutions
    - Contrast&Care^® Injection Management Solution
    - icobrain dm
- CT
  - Contrast Agents
  - Injectors, Accessories & Consumables
  - Service & Support
    - OptiProtect™ 3S
  - Digital Solutions
    - Contrast&Care^® Injection Management Solution
    - icobrain dm
- Cath Lab
  - Contrast Agents
    - Xenetix^® / ScanBag^® by Xenetix^®
    - Optiray^®
  - Injectors, Accessories & Consumables
  - Service & Support
    - OptiProtect™ 3S
  - Digital Solutions
    - Contrast&Care^® Injection Management Solution
- Interventional Radiology
  - Pharmaceutical Drugs
    - Lipiodol^® Ultra Fluid
- Women's Health
  - Pharmaceutical Drugs
    - Lipiodol^® Ultra Fluid
    - Patent Blue V
- Urology
  - Urology
    - Hydra Vision™ Digital Imaging System
    - Urology Accessories & Consumables
Investors
Media
Educational Resources
Patient Resources

Optimizing treatment approaches for HCC today | CIRSE 2022 On-demand

Optimizing treatment approaches for HCC today | CIRSE 2022 On-demand

Homepage Insights Optimizing treatment approaches for HCC today

Chairman Prof. Thierry De Baere (Villejuif, France)

Register below to watch the replay 💻

Media
Legal Information
Cookie Policy
Universal Registration Document 2023
Patents
Contact

Copyright © Guerbet 2022

LinkedIn
Twitter
Instagram
YouTube

Copyright © Guerbet 2022